bioRxiv / medRxiv
open access
CC BY-NC-ND 4.0
Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: A subgroup analysis optimizing the benefit-risk profile of masitinib
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Quantifying motor unit loss prior to functional impairment in muscles affected by amyotrophic lateral sclerosis.#360658
- This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling#867967
- Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis#980761
- Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)#1033121
- Living with Amyotrophic Lateral Sclerosis: Exploring what matters to patients and caregivers through their experiences.#678216
Record · ID 29760
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive